Close Menu

NEW YORK ─ Todos Medical on Monday announced a $3.4 million strategic investment in its business by venture capital firm Yozma Group Korea.

Under the terms of the agreement, Yozma has been issued a one-year, $3.4 million promissory note convertible into common shares at a fixed price of $0.0599 per share, Todos said.

Rehovot, Israel-based Todos said it intends to use the proceeds for general working capital, to retire outstanding convertible notes, and to complete the acquisition of proteomics test developer Provista Diagnostics.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.